CHILDREN'S DIMETAPP COLD & ALLERGY CHEWABLE TABLETS OTC
Generic Name and Formulations:
Brompheniramine maleate 1mg, phenylephrine HCl 2.5mg; per tab; alcohol-free; grape flavor.
Pfizer Consumer Healthcare
Indications for CHILDREN'S DIMETAPP COLD & ALLERGY CHEWABLE TABLETS:
Rhinorrhea, allergy symptoms, nasal congestion.
<6yrs: do not use. 6–11yrs: chew 2 tabs every 4 hours; max 6 doses/24 hours.
Children <6yrs old. During or within 14 days of MAOIs. For use as a sedative hypnotic.
Hypertension. Cardiovascular disease. Thyroid disease. Diabetes. Glaucoma. GI or GU obstruction. Asthma. Lower respiratory disorders. Pregnancy. Nursing mothers.
See Contraindications. Hypertensive crisis with MAOIs. β-blockers may increase pressor effects of sympathomimetics. Antihypertensives antagonized. Increased CNS effects with other CNS depressants. Avoid alcohol.
Antihistamine + sympathomimetic.
Drowsiness, anticholinergic effects, dizziness, nervousness, insomnia, excitability in children.
Syrup—4oz, 8oz (w. dosing cup)
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|